Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Saturday
May 18th
Home arrow Farmavita.Net Journal arrow Biomarkers in Drug Discovery
Biomarkers in Drug Discovery Print E-mail
Business Reports - Product Report

gbi.jpg

Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Cost

GBI Research's new report "Biomarkers in Drug Discovery - Optimizing Drug Discovery Timeline and Cost" provides an in-depth analysis on the potential applications of biomarkers in pharmaceutical drug discovery and clinical services. The report suggests investment decisions in biomarker based drug research by providing information on valid biomarkers, pipelines, case studies, competitive landscape, geographical dominance, mergers and acquisitions and market potential. It also provides an analysis on the trends prevailing in the global biomarkers market. In addition to this, the report also covers market drivers and Restrains for the global biomarkers market.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Increasing Acceptance and Application of Biomarkers in Drug Discover by Pharmaceutical Companies

GBI Research analyzed the increasing application of Biomarkers in drug discovery process and how it facilitates the Pharmaceutical Companies to overcome the challenges posed by conventional drug discovery processes which are time consuming and expensive. High drug attrition rates, safety and efficacy concerns and time consuming methods have encouraged the pharmaceuticals sector to adopt the use of biomarkers in drug discovery process on a large scale. According to the FDA the biomarkers are 10% more efficient in predicting drug failures and hence can save approximately $100m and three to four years in each drug discovery process. Application of the biomarkers in the pharmaceuticals sector can revolutionize the drug discovery process by facilitating treatment decision and introduction of preventive and personalized medicines.

Application of Biomarkers in Each Stage of Drug Discovery

Biomarkers have wide spread applications and are used in several sectors including pharmaceuticals due to their high sensitivity and efficacy. In the pharmaceuticals sector biomarkers have applications in each phase of drug discovery. In drug discovery processes biomarkers are used mainly to monitor the disease progression with the therapy. The reason for their popularity in the pharmaceuticals sector constitutes its ability to detect and monitor disease progression. Biomarkers techniques are non-invasive and robust and have helped them gain popularity over the conventional drug discovery methods. From the early lead and target identification and optimization stages to late stage drug discovery process biomarkers are applicable for target validation, determination of mechanism of action of drug (MOA), drug safety and efficacy and most importantly the therapy response. Biomarkers are applicable in efficiently and accurately studying dosage response during clinical trials stratifying patient population and facilitating faster filings and post marketing surveillance. The efficient integration of biomarkers in each drug discovery stage allows pharmaceutical companies to save time and money on R&D to enhance their pipeline. Pharmaceutical companies wanting to reduce their drug discover cost and time are widely applying novel and validated biomarkers.

Wide Spread Use, Flexible FDA Regulations and Integration of ‘Omics' Drive Biomarkers Market towards Growth

GBI Research has analyzed the factors driving the Biomarkers market towards steady growth. Biomarkers have widespread application in the pharmaceuticals and Disease diagnosis sector. The FDA is somehow flexible in regulating the application of biomarkers in the drug discovery process. This is the key factor contributing to the growth of the biomarkers market. Also the fact that biomarkers application in the drug discovery process involves the integration of the ‘Omics' technologies like the proteomics, genomics, transcriptomics and others is causing tremendous growth of the biomarkers market. The fact that biomarkers predict accurate safety profile are cost effective and time consuming are those factors open wide scope for the growth of the biomarker application by the pharmaceuticals companies.

Biomarkers Facilitating Quick Turnover of Drugs

Conventional Drug discovery methods are expensive and time consuming. Each drug discovery requires approximately 12-15 years and an expenditure of $800M. According to the FDA biomarkers facility in reducing the over all drug discovery time span to 8-12 years and cut down developmental cost by $100M. Faster and efficient disease progression in each drug discovery stage have caused quick turn over of drugs and helped the pharmaceuticals sector and also the diseased population.

Biomarkers Market Expects Significant Growth

GBI Research concludes the advantages of biomarker applications in the drug discovery process by the pharmaceuticals sector and their increased growth. The global biomarkers market is a relatively mature market with approximately $6.3 billion worth revenues in the year 2008. Since 2000 the market has seen extensive growth due to increase in application of biomarkers in molecular diagnostics and clinical services. But its application in drug discovery has been recently realized by the pharmaceutical sector and has a share of 44% in 2008 of the global biomarkers market. By 2015 the market is expected to attain revenues worth $22.2 billion due to expected regulatory and validation procedures for biomarkers to be done by the regulatory bodies. Also rise in awareness and ability to fulfill unmet needs posed by the conventional drug discovery approaches will drive market towards significant growth.

About GBI Research

GBI Research is a leading business information company providing global business information reports and services. Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

If you have any queries about this report or would like further information, please contact

North America: +1 646 395 5477
Europe: +44 207 753 4299 
            +44 161 227 0669
Asia Pacific: +91 40 6616 6767

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Comments
Add New Search RSS
Write comment
Name:
Email:
 
Website:
Title:
 
Please input the anti-spam code that you can read in the image.

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."

Read also at Pharmaceutical Licensing Network
Newer news items
Related Items
Farmavita.Net - The Pharmaceutical Licensing Network




Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Blogmarks!Yahoo!Ma.gnolia!FeedMeLinks!Free social bookmarking plugins and extensions for Joomla! websites!
 
< Prev   Next >
Advertisement
 

Featured Partners

 
logo_kvadrat_150x150.jpg    
lcm-150x150.jpg  
bals134_150x150.jpg
150-150-static.gif
apacma13_150x150_banner.gif  
  doctors20150x1501.png
bals137_150x150.gif
bals138_150x150.jpg
ch-150x150-an.gif 

Login to Farmavita.Net

membership is FREE

Follow us on:




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 11 guests online

Farmavita.Net RSS News


Reports

rbdl0002_innovations-in-inj.gif 

Events

150-150-static.gif

Reports

rbhc0264_privatehealthcare.gif 

REPORTS

farmavita_research-store.gif